Radiation Therapy for Colorectal Cancer

Hee Chul Park; Doo Ho Choi

doi:10.5124/jkma.2010.53.7.592

Journal List > J Korean Med Assoc > v.53(7) > 1042295

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Park and Choi: Radiation Therapy for Colorectal Cancer

Focused Issue of This Month

Colorectal Cancer

Journal of the Korean Medical Association

Journal of the Korean Medical Association 2010; 53(7): 592-602.

Published online: 6 July 2010

DOI: https://doi.org/10.5124/jkma.2010.53.7.592

Radiation Therapy for Colorectal Cancer

Hee Chul Park, MD, Doo Ho Choi, MD

Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Corresponding author: Doo Ho Choi. dohochoi@skku.edu

Received 27 May 2010 Accepted 10 June 2010

(open-access):

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Treatment for high-risk colorectal cancer has evolved from surgical resection alone to the selective use of multimodalities such as chemotherapy and radiation therapy (RT). Postoperative RT can eradicate microscopic disease after surgical resection and preoperative RT leads to decreased tumor burden before the commencement of operation. The role of RT in the management of colon cancer is not confirmatory as of now. While there is some suspicion, no critical evidence can be found. However, some retrospective data support the role of RT to improve the prognosis in patients with colon cancer. Postoperative RT combined with chemotherapy can reduce the locoregional recurrences and exert a critical influence on patients' quality of life. Preoperative RT alone or the combination with chemotherapy down-stages the tumor to decrease the operative morbidity, and promotes the sphincter preservation. Preoperative RT improves local control. In addition, down-staging after neoadjuvant treatment merits attention as prognosticator. Patients who have had better tumor response also had superior survival profile. Treatment approach to locally advanced rectal cancer is changing from postoperative adjuvant one to aggressive application of preoperative modality. Future research efforts will focus the optimal treatment strategies to fortify the complete or near complete response rates. The recent advances in RT technology are also being examined to see whether the tumor response can be enhanced while decreasing toxicity so that more intensive chemotherapy regimens can be combined with RT. This review will trace the evolution of multimodality approach to locally advanced colorectal cancer.

Keywords: Colon cancer, Rectal cancer, Radiation therapy

Figures and Tables

Figure 1

Radiotherapy (RT) planning comparison between intensity modulated radiation therapy (IMRT) and conventional RT. (A) Isodose distribution. IMRT covers the target more conformal than conventional RT. (B) Dose volume histogram. With the same coverage of RT target, small bowel is less irradiated with IMRT.

References

1. Kim JH. Role of radiotherapy in high-risk colon cancer. J Korean Med Assoc. 2002. 45:842–850.

2. Willett CG, Fung CY, Kaufman DS, Efird J, Shellito PC. Postoperative radiation therapy for high-risk colon carcinoma. J Clin Oncol. 1993. 11:1112–1117.

3. Martenson JA Jr, Willett CG, Sargent DJ, Mailliard JA, Donohue JH, Gunderson LL, Thomas CR Jr, Fisher B, Benson AB 3rd, Myerson R, Goldberg RM. Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. J Clin Oncol. 2004. 22:3277–3283.

4. Amos EH, Mendenhall WM, McCarty PJ, Gage JO, Emlet JL, Lowrey GC, Peterson CA, Amos WR. Postoperative radiotherapy for locally advanced colon cancer. Ann Surg Oncol. 1996. 3:431–436.

5. Fabian C, Giri S, Estes N, Tangen CM, Poplin E, Vogel S, Goodwin W, Rivkin S, Fleming TR, Macdonald JS. Adjuvant continuous infusion 5-FU, whole-abdominal radiation, and tumor bed boost in high-risk stage III colon carcinoma: a Southwest Oncology Group Pilot study. Int J Radiat Oncol Biol Phys. 1995. 32:457–464.

6. The Gastrointestinal Tumor Study Group. Adjuvant therapy with hepatic irradiation plus fluorouracil in colon carcinoma. Int J Radiat Oncol Biol Phys. 1991. 21:1151–1156.

7. Mendenhall WM, Million RR, Pfaff WW. Patterns of recurrence in adenocarcinoma of the rectum and rectosigmoid treated with surgery alone: implications in treatment planning with adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 1983. 9:977–985.

8. Rich T, Gunderson LL, Lew R, Galdibini JJ, Cohen AM, Donaldson G. Patterns of recurrence of rectal cancer after potentially curative surgery. Cancer. 1983. 52:1317–1329.

9. Douglass HO Jr, Moertel CG, Mayer RJ, Thomas PR, Lindblad AS, Mittleman A, Stablein DM, Bruckner HW. Survival after postoperative combination treatment of rectal cancer. N Engl J Med. 1986. 315:1294–1295.

10. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Mailliard JA, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991. 324:709–715.

11. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990. 264:1444–1450.

12. O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, Mayer RJ, Gunderson LL, Rich TA. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994. 331:502–507.

13. Tepper JE, O'Connell M, Niedzwiecki D, Hollis DR, Benson AB 3rd, Cummings B, Gunderson LL, Macdonald JS, Martenson JA, Mayer RJ. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control-final report of intergroup 0114. J Clin Oncol. 2002. 20:1744–1750.

14. Lee JH, Lee JH, Ahn JH, Bahng H, Kim TW, Kang YK, Lee KH, Kim JC, Yu CS, Kim JH, Ahn SD, Kim WK, Kim SH, Lee JS. Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemo-therapy and radiotherapy: a preliminary report. J Clin Oncol. 2002. 20:1751–1758.

15. Kim YS, Kim JH, Choi EK, Ahn SD, Lee S, Kim KJ, Lee JH, Kim JC, You CS, Kim HC. Optimal scheme of postoperative chemoradiotherapy in rectal cancer: Phase III prospective randomized trial. J Korean Soc Ther Radiol Oncol. 2002. 20:53–61.

16. Fisher B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham DL, Fisher ER, Caplan R, Jones J, Lerner H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 1988. 80:21–29.

17. Wolmark N, Wieand HS, Hyams DM, Colangelo L, Dimitrov NV, Romond EH, Wexler M, Prager D, Cruz AB Jr, Gordon PH, Petrelli NJ, Deutsch M, Mamounas E, Wickerham DL, Fisher ER, Rockette H, Fisher B. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst. 2000. 92:388–396.

18. Gunderson LL, Sargent DJ, Tepper JE, O'Connell MJ, Allmer C, Smalley SR, Martenson JA, Haller DG, Mayer RJ, Rich TA, Ajani JA, Macdonald JS, Goldberg RM. Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. Int J Radiat Oncol Biol Phys. 2002. 54:386–396.

19. Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O'Connell MJ, Begovic M, Allmer C, Colangelo L, Smalley SR, Haller DG, Martenson JA, Mayer RJ, Rich TA, Ajani JA, MacDonald JS, Willett CG, Goldberg RM. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol. 2004. 22:1785–1796.

20. Withers HR, Haustermans K. Where next with preoperative radiation therapy for rectal cancer? Int J Radiat Oncol Biol Phys. 2004. 58:597–602.

21. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997. 336:980–987.

22. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ. Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001. 345:638–646.

23. Peeters KC, van de Velde CJ, Leer JW, Martijn H, Junggeburt JM, Kranenbarg EK, Steup WH, Wiggers T, Rutten HJ, Marijnen CA. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients-a Dutch colorectal cancer group study. J Clin Oncol. 2005. 23:6199–6206.

24. Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, Rutten H, Pahlman L, Glimelius B, Leer JW, van de Velde CJ. Dutch Colorectal Cancer Group. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007. 246:693–701.

25. Crane CH, Skibber JM, Feig BW, Vauthey JN, Thames HD, Curley SA, Rodriguez-Bigas MA, Wolff RA, Ellis LM, Delclos ME, Lin EH, Janjan NA. Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma. Cancer. 2003. 97:517–524.

26. Minsky BD. Sphincter preservation in rectal cancer. Preoperative radiation therapy followed by low anterior resection with coloanal anastomosis. Semin Radiat Oncol. 1998. 8:30–35.

27. Wagman R, Minsky BD, Cohen AM, Guillem JG, Paty PP. Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up. Int J Radiat Oncol Biol Phys. 1998. 42:51–57.

28. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R. German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004. 351:1731–1740.

29. Guillem JG, Díaz-González JA, Minsky BD, Valentini V, Jeong SY, Rodriguez-Bigas MA, Coco C, Leon R, Hernandez-Lizoain JL, Aristu JJ, Riedel ER, Nitti D, Wong WD, Pucciarelli S. cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol. 2008. 26:368–373.

30. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006. 93:1215–1223.

31. Siegel R, Burock S, Wernecke KD, Kretzschmar A, Dietel M, Loy V, Koswig S, Budach V, Schlag PM. Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society. BMC Cancer. 2009. 9:50.

32. Collette L, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P, Radosevic-Jelic L, Piérart M, Calais G. European Organisation for Research and Treatment of Cancer Radiation Oncology Group. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol. 2007. 25:4379–4386.

33. Rödel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005. 23:8688–8696.

34. Stipa F, Chessin DB, Shia J, Paty PB, Weiser M, Temple LK, Minsky BD, Wong WD, Guillem JG. A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography. Ann Surg Oncol. 2006. 13:1047–1053.

35. Kim TH, Chang HJ, Kim DY, Jung KH, Hong YS, Kim SY, Park JW, Oh JH, Lim SB, Choi HS, Jeong SY. Pathologic Nodal Classification Is the Most Discriminating Prognostic Factor for Disease-Free Survival in Rectal Cancer Patients Treated with Preoperative Chemoradiotherapy and Curative Resection. Int J Radiat Oncol Biol Phys. 2009.

36. Kim TH, Jeong SY, Choi DH, Kim DY, Jung KH, Moon SH, Chang HJ, Lim SB, Choi HS, Park JG. Lateral lymph node metastasis is a major cause of locoregional recurrence in rectal cancer treated with preoperative chemoradiotherapy and curative resection. Ann Surg Oncol. 2008. 15:729–737.

37. Baglan KL, Frazier RC, Yan D, Huang RR, Martinez AA, Robertson JM. The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2002. 52:176–183.

38. Gallagher MJ, Brereton HD, Rostock RA, Zero JM, Zekoski DA, Poyss LF, Richter MP, Kligerman MM. A prospective study of treatment techniques to minimize the volume of pelvic small bowel with reduction of acute and late effects associated with pelvic irradiation. Int J Radiat Oncol Biol Phys. 1986. 12:1565–1573.

39. Guerrero Urbano MT, Henrys AJ, Adams EJ, Norman AR, Bedford JL, Harrington KJ, Nutting CM, Dearnaley DP, Tait DM. Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. Int J Radiat Oncol Biol Phys. 2006. 65:907–916.

40. Freedman GM, Meropol NJ, Sigurdson ER, Hoffman J, Callahan E, Price R, Cheng J, Cohen S, Lewis N, Watkins-Bruner D, Rogatko A, Konski A. Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2007. 67:1389–1393.

41. De Ridder M, Tournel K, Van Nieuwenhove Y, Engels B, Hoorens A, Everaert H, Op de Beeck B, Vinh-Hung V, De Gréve J, Delvaux G, Verellen D, Storme GA. Phase II study of preoperative helical tomotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2008. 70:728–734.

42. Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009. 27:3020–3026.

TOOLS

Similar articles